Not Signed In -
Valganciclovir |
Valcyte |
Image:Valganciclovir.png Valganciclovir Systematic (IUPAC) name ? Identifiers CAS number ? ATC code J05AB14 PubChem 64147 Chemical data Formula C14H22N6O5 Mol. weight 354.362 Pharmacokinetic data Bioavailability ? Metabolism ? Half life ? Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Valganciclovir hydrochloride (Valcyte®) is an antiviral medication used to treat cytomega ...
Wikipedia - [full article]
Valganciclovir Clinical Trials
- Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00016068 - Active, not recruiting
Infection
- Assessment of valganciclovir in neonates with CMV
ClinicalTrials.gov Identifier: NCT00031434 - Active, not recruiting
Cytomegalovirus Infections
- Valganciclovir in Patients with CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
ClinicalTrials.gov Identifier: NCT00017784 - Active, not recruiting
Cytomegalovirus Retinitis; HIV Infections
- Valganciclovir to Reduce T Cell Activation in HIV Infection
ClinicalTrials.gov Identifier: NCT00264290 - Recruiting
HIV Infections; Cytomegalovirus Infections
- Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
ClinicalTrials.gov Identifier: NCT00096538 - Recruiting
classic Kaposi's sarcoma; recurrent Kaposi's sarcoma
- Safety and Pharmacokinetics of Valganciclovir syrup formulation in pediatric solid organ transplant recipients
ClinicalTrials.gov Identifier: NCT00090766 - Completed
Cytomegalovirus Infection
- A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
ClinicalTrials.gov Identifier: NCT00372229 - Recruiting
Cytomegalovirus Infections
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
ClinicalTrials.gov Identifier: NCT00294515 - Active, not recruiting
Cytomegalovirus Infections
- Valganciclovir in Prevention of CMV Reactivation Following Allo-SCT
ClinicalTrials.gov Identifier: NCT00330018 - Recruiting
Bone Marrow Transplantation; Cytomegalovirus
- WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
ClinicalTrials.gov Identifier: NCT00275314 - Terminated
Kidney Transplant
- VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
ClinicalTrials.gov Identifier: NCT00431353 - Active, not recruiting
Cytomegalovirus Infections
- The Study is Being Done to See If Taking the Drug Valganciclovir Can Prevent CMV Infection.
ClinicalTrials.gov Identifier: NCT00275665 - Recruiting
Bone Marrow Stem Cell Transplant
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
ClinicalTrials.gov Identifier: NCT00227370 - Recruiting
Cytomegalovirus Infections
- Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
ClinicalTrials.gov Identifier: NCT00478465 - Active, not recruiting
Chronic Fatigue Syndrome
- Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
ClinicalTrials.gov Identifier: NCT00387530 - Recruiting
Gastric Cancer; Head and Neck Cancer; Lymphoma
- Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
ClinicalTrials.gov Identifier: NCT00361933 - Not yet recruiting
Giant Lymph Node Hyperplasia
- Pharmacokinetics of Mmf and Valganciclovir
ClinicalTrials.gov Identifier: NCT00189150 - Recruiting
Kidney Transplant Recipient; Heart Transplant Recipient
- Primary Effusion Lymphoma: A Pilot Trial Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy with Bortezomib, Zidovudine and Valganciclovir
ClinicalTrials.gov Identifier: NCT00121576 - Recruiting
- Preventing Cytomegalovirus (CMV) Organ Damage with Valganciclovir in People with HIV
ClinicalTrials.gov Identifier: NCT00006145 - Completed
Cytomegalovirus Infections; HIV Infections
- A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
ClinicalTrials.gov Identifier: NCT00002377 - Completed
Cytomegalovirus Retinitis; HIV Infections
- A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients with AIDS
ClinicalTrials.gov Identifier: NCT00002222 - Completed
Cytomegalovirus Retinitis; HIV Infections
- MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
ClinicalTrials.gov Identifier: NCT00237653 - Recruiting
Cytomegalovirus Infections; Inflammatory Bowel Diseases
- Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
ClinicalTrials.gov Identifier: NCT00466817 - Not yet recruiting
Cytomegalovirus Infections
- Study of Prophylactic Vs Preemptive Valganciclovir
ClinicalTrials.gov Identifier: NCT00374686 - Completed
Cytomegalovirus Infection
- Suppression of Oral HHV8 Shedding With Valganciclovir
ClinicalTrials.gov Identifier: NCT00194467 - Completed
Human Herpesvirus 8
- Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients
ClinicalTrials.gov Identifier: NCT00198224 - Completed
Renal Failure
- A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
ClinicalTrials.gov Identifier: NCT00377741 - Completed
Cytomegalovirus Infections
- Oral Valganciclovir Versus Valacyclovir
ClinicalTrials.gov Identifier: NCT00562770 - Completed
Chronic Lymphocytic Leukemia; Leukemia
- Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients
ClinicalTrials.gov Identifier: NCT00225394 - Completed
CMV Disease; Viral Resistance; Rejection; Death
- Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00241345 - Suspended
Cytomegalovirus Infections
Resources
- Valcyte (Drug Digest)
- Valganciclovir (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
